RU2358735C2 - Агонисты м1 мускариновых рецепторов для противоболевой терапии - Google Patents

Агонисты м1 мускариновых рецепторов для противоболевой терапии Download PDF

Info

Publication number
RU2358735C2
RU2358735C2 RU2005133197/14A RU2005133197A RU2358735C2 RU 2358735 C2 RU2358735 C2 RU 2358735C2 RU 2005133197/14 A RU2005133197/14 A RU 2005133197/14A RU 2005133197 A RU2005133197 A RU 2005133197A RU 2358735 C2 RU2358735 C2 RU 2358735C2
Authority
RU
Russia
Prior art keywords
optionally substituted
alkyl
group
aryl
alkynyl
Prior art date
Application number
RU2005133197/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2005133197A (ru
Inventor
Роберт Р. ДЭВИС (US)
Роберт Р. ДЭВИС
Кимберли ВАНОВЕР (US)
Кимберли ВАНОВЕР
Марио РОДРИГЕС (US)
Марио РОДРИГЕС
Original Assignee
Акадиа Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акадиа Фармасьютикалз Инк. filed Critical Акадиа Фармасьютикалз Инк.
Publication of RU2005133197A publication Critical patent/RU2005133197A/ru
Application granted granted Critical
Publication of RU2358735C2 publication Critical patent/RU2358735C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2005133197/14A 2003-03-28 2004-03-26 Агонисты м1 мускариновых рецепторов для противоболевой терапии RU2358735C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45904503P 2003-03-28 2003-03-28
US60/459,045 2003-03-28

Publications (2)

Publication Number Publication Date
RU2005133197A RU2005133197A (ru) 2006-04-27
RU2358735C2 true RU2358735C2 (ru) 2009-06-20

Family

ID=33131858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005133197/14A RU2358735C2 (ru) 2003-03-28 2004-03-26 Агонисты м1 мускариновых рецепторов для противоболевой терапии

Country Status (13)

Country Link
US (1) US20050130961A1 (cg-RX-API-DMAC7.html)
EP (1) EP1613321A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006521399A (cg-RX-API-DMAC7.html)
KR (1) KR20050112116A (cg-RX-API-DMAC7.html)
CN (1) CN1777425A (cg-RX-API-DMAC7.html)
AU (1) AU2004226430A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409523A (cg-RX-API-DMAC7.html)
CA (1) CA2520125A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05010171A (cg-RX-API-DMAC7.html)
NZ (1) NZ542690A (cg-RX-API-DMAC7.html)
RU (1) RU2358735C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004087158A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200508733B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
AU2002359875B2 (en) * 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
US20080015225A1 (en) * 2004-07-16 2008-01-17 Janssen Pharmaceutica N.V. Dimeric Piperidine Derivatives
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010504359A (ja) 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CA2712731C (en) 2008-01-22 2016-05-03 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP2016513677A (ja) * 2013-03-15 2016-05-16 アカディア ファーマシューティカルズ インコーポレイテッド ムスカリンアゴニスト
ES2811088T3 (es) 2014-04-23 2021-03-10 Takeda Pharmaceuticals Co Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
JP2022523355A (ja) * 2019-02-22 2022-04-22 カルナ セラピューティックス，インコーポレイテッド 神経障害の処置のための重水素化キサノメリンの化合物及び方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2160098C2 (ru) * 1996-04-05 2000-12-10 Галдерма Ресерч энд Девелопмент, С.Н.С. Применение бензонафталиновых производных для получения лекарственных средств, предназначенных для лечения заболеваний нервной системы
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
WO2001083472A1 (en) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5155166A (en) * 1990-06-18 1992-10-13 Eastman Kodak Company Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
GB2292685A (en) * 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
WO2000030632A1 (en) * 1998-11-23 2000-06-02 Eisai Co., Ltd. Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists
RU2288919C2 (ru) * 2001-10-02 2006-12-10 Акадиа Фармасьютикалз, Инк. Производные бензимидазолидинона в качестве агентов мускариновых рецепторов
AU2002359875B2 (en) * 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
RU2160098C2 (ru) * 1996-04-05 2000-12-10 Галдерма Ресерч энд Девелопмент, С.Н.С. Применение бензонафталиновых производных для получения лекарственных средств, предназначенных для лечения заболеваний нервной системы
WO2001083472A1 (en) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HWANG J.H. et al. The antiallodynic effects of intrathecal cholinesterase inhibitors in a rat model of neuropathic pain. Anesthesiology. 1999 Feb; 90(2):492-9, реферат, он-лайн [Найдено в Интернет на (www.pubmed.com) 29.12.2007], PMID: 9952157 [PubMed - indexed for MEDLINE]. GHELARDINI С. et al. Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats. Neuropharmacology. 2002 Dec; 43(7):1180-7. реферат, он-лайн [Найдено в Интернет на (www.pubmed.com) 29.12.2007], PMID: 12504925 [PubMed - indexed for MEDLINE]. OBATA H. et al. Possible involvement of a muscarinic receptor in the anti-allodynic action of a 5-HT2 receptor agonist in rats with nerve ligation injury. Brain Res. 2002 Apr.5; 932(1-2):124-8. реферат, он-лайн [Найдено в Интернет на (www.pubmed.com) 29.12.2007], PMID: 11911869 [PubMed - indexed for MEDLINE]. *

Also Published As

Publication number Publication date
WO2004087158A2 (en) 2004-10-14
ZA200508733B (en) 2006-09-27
EP1613321A2 (en) 2006-01-11
JP2006521399A (ja) 2006-09-21
KR20050112116A (ko) 2005-11-29
WO2004087158A3 (en) 2005-03-31
BRPI0409523A (pt) 2006-04-18
NZ542690A (en) 2009-04-30
RU2005133197A (ru) 2006-04-27
MXPA05010171A (es) 2005-12-12
CN1777425A (zh) 2006-05-24
AU2004226430A1 (en) 2004-10-14
CA2520125A1 (en) 2004-10-14
US20050130961A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
US20050130961A1 (en) Muscarinic M1 receptor agonists for pain management
EP1045693B1 (en) Aminophenoxyacetic acid derivatives as neuroprotectants
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
ES2225143T3 (es) Derivados de aminas ciclicas y sus usos.
JP2002069004A (ja) 末梢性活性抗痛覚過敏オピエート
JP6528779B2 (ja) びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
EP1100495A1 (en) Propenamides as ccr5 modulators
TW200940526A (en) Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
IL118328A (en) Use of a combination of a forebrain selective N-methyl-D-aspartate antagonist and excitatory feedback enhancing agent in the preparation of pharmaceutical composition for treating Parkinson's disease
WO2002005819A1 (en) Compounds and methods
NZ299376A (en) Treating tinnitus using piperidine, pyrrolidine or 8-aza-bicyclo[3.2.1]octane derivatives
RU2333200C2 (ru) Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил
WO2004010942A2 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
US20050136444A1 (en) Treating neuropathic pain with neuropeptide FF receptor 2 agonists
WO2002058687A2 (en) Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics
AU779152B2 (en) Prophylactic use of N-methyl-D-aspartate (NMDA) antagonists
JP2000309545A (ja) 愛玩動物の年齢関連行動障害治療方法および治療用組成物
EP0655246A1 (en) Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
CN120225192A (zh) 用于治疗神经退行性疾病的哌啶脲衍生物
US6103712A (en) Therapeutic treatment for asthma
EP0659409A2 (en) Substance 1 antagonists for the inhibition of angiogenesis
AU2018215466A1 (en) Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof
JPH07503240A (ja) ３‐アリールインドールおよび１‐アリールインダゾール誘導体の精神病の治療のための使用
WO2026072624A1 (en) Piperidine urea derivatives for obesity therapy